News

The company said that ANA598 demonstrates significant antiviral activity in vivo. Two animals chronically infected with hepatitis C virus (HCV) genotype 1b each received once-daily oral doses of

Bedford Laboratories is now the reference listed drug holder. Bedford Laboratories will supply latex-free Cafcit (caffeine citrate) injection as 60mg/3 mL single-use vials individually boxed and Cafcit oral

Alogliptin (SYR-322) was designed to selectively inhibit dipeptidyl peptidase-4 (DPP-4) taken orally once daily. The new drug application (NDA) submission was supported by six Phase III clinical trials

The debentures mature the earlier of November 1, 2012 or the sale of the company. The debentures, together with all accrued and unpaid interest thereon, may be repaid,

The new drug application (NDA) filing is based on global studies conducted in more than 20 countries. These studies evaluated more than 6,000 subjects with erosive and non-erosive

The new, mobile positron emission tomography and computed tomography (PET-CT) systems will simplify treatment follow-up for many patients. The system has been completely redesigned to incorporate hardware improvements

The new Japanese trial is a 28 day, double-masked, dose-ranging study, in which approximately 120 Japanese patients with primary open-angle glaucoma or ocular hypertension, in one or both

BioFocus will apply Galapagos’s proprietary adenoviral platform to identify novel drug targets for the development of cancer therapies. The goal of the new collaboration will be to discover

Under the terms of the agreement, Crucell will continue to perform the development activities and will manufacture the final product. Crucell will receive a payment of E10 million